FY2029 Earnings Forecast for AVTE Issued By Wedbush

Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) - Equities researchers at Wedbush issued their FY2029 earnings per share estimates for shares of Aerovate Therapeutics in a report released on Monday, February 24th. Wedbush analyst L. Chico forecasts that the company will earn ($0.74) per share for the year. The consensus estimate for Aerovate Therapeutics' current full-year earnings is ($2.64) per share.

Aerovate Therapeutics Price Performance

Shares of Aerovate Therapeutics stock traded up $0.01 during trading on Wednesday, reaching $2.43. 121,336 shares of the stock traded hands, compared to its average volume of 182,188. The company has a market capitalization of $70.17 million, a price-to-earnings ratio of -0.81 and a beta of 0.99. The business has a fifty day simple moving average of $2.54 and a two-hundred day simple moving average of $2.35. Aerovate Therapeutics has a 52-week low of $1.25 and a 52-week high of $32.42.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Jefferies Financial Group Inc. purchased a new position in shares of Aerovate Therapeutics during the fourth quarter valued at about $1,590,000. GTS Securities LLC purchased a new position in Aerovate Therapeutics in the fourth quarter worth about $27,000. Squarepoint Ops LLC purchased a new position in Aerovate Therapeutics in the fourth quarter worth about $52,000. Two Sigma Advisers LP grew its position in Aerovate Therapeutics by 38.5% in the fourth quarter. Two Sigma Advisers LP now owns 153,600 shares of the company's stock worth $407,000 after acquiring an additional 42,700 shares in the last quarter. Finally, Bridgeway Capital Management LLC purchased a new position in Aerovate Therapeutics in the fourth quarter worth about $159,000.

Remove Ads

Aerovate Therapeutics Company Profile

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.